Jagsonpal Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Jagsonpal Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 184.3 times. Higher than almost all Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹75 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 88% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 29.7 times by its yearly operating cash. Higher than 88% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹113Over the last 3 years, every ₹100 of reported profit came with ₹113 of operating cash.
Higher than 52% of Healthcare companies in India.
Self-Funding Ratio
100×+Over the last 3 years its own operating cash covered its investment spending (capex) 184.3 times.
Higher than almost all Healthcare companies in India.
Cash Locked Ratio
₹3For every ₹100 of sales, ₹3 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹7 tied up three years earlier.
Less money tied up than 82% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
₹32Sales grew 21% in 3 years; of every extra ₹100 of sales, ₹32 became extra profit.
Higher than 81% of Healthcare companies in India.
Asset Productivity Ratio
+21% / +62%In 3 years sales changed by +21% while total assets changed by +62%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
29.7×Debt due within a year is covered 29.7 times by its yearly operating cash.
Higher than 88% of Healthcare companies in India.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Higher than 87% of Healthcare companies in India.
Tangible Assets Ratio
75%Of every ₹100 the company owns, ₹75 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 88% of Healthcare companies in India.
Tangible Net Worth Ratio
72%Of every ₹100 of net worth, ₹72 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 79% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Jagsonpal Pharmaceuticals Limited owes ₹0.13 for every ₹1 it owns. Net profit fell 22% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
31.4Investors pay ₹31.4 for every ₹1 of Jagsonpal Pharmaceuticals Limited's yearly profit, lower than 60% of Healthcare companies in India.
P/B ratio
5.04The share price is 5.04 times Jagsonpal Pharmaceuticals Limited's book value per share, higher than 54% of Healthcare companies in India.
Market cap
₹1,393 CrThe total market value of all of Jagsonpal Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹276 CrWhat Jagsonpal Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹41.81Net worth divided by the number of shares. The share price of ₹210.86 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
17.0%Jagsonpal Pharmaceuticals Limited earned 17.0% on its shareholders' money over the last year, higher than 67% of Healthcare companies in India.
Owes vs Owns
0.13×Jagsonpal Pharmaceuticals Limited owes ₹0.13 for every ₹1 it owns (low), lower than 96% of Healthcare companies in India.
Dividend yield
1.11%Jagsonpal Pharmaceuticals Limited pays 1.11% of its share price as dividends a year, higher than 82% of dividend-paying Healthcare companies in India.
Revenue growth
+7%Revenue rose 7% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit growth
-22%Net profit fell 22% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit margin
15.0%Jagsonpal Pharmaceuticals Limited keeps ₹15 of every ₹100 of revenue as net profit.
Cash quality
1.09×Cash from Jagsonpal Pharmaceuticals Limited's business was 1.09× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
58.4×Jagsonpal Pharmaceuticals Limited's operating profit covered its interest costs 58.4 times in the year to Mar 2026.
Cash vs debt
Net cashJagsonpal Pharmaceuticals Limited held ₹98 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Jagsonpal Pharmaceuticals Limited's P/E ratio?
Investors pay ₹31.4 for every ₹1 of Jagsonpal Pharmaceuticals Limited's yearly profit, lower than 60% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Jagsonpal Pharmaceuticals Limited: ₹1,393 Cr ÷ ₹276 Cr (31 Mar 2026) = 5.0.
What is Jagsonpal Pharmaceuticals Limited's return on equity?
Jagsonpal Pharmaceuticals Limited earned 17.0% on its shareholders' money over the last year, higher than 67% of Healthcare companies in India.
How much does Jagsonpal Pharmaceuticals Limited owe compared with what it owns?
Jagsonpal Pharmaceuticals Limited owes ₹0.13 for every ₹1 it owns (low), lower than 96% of Healthcare companies in India.
Does Jagsonpal Pharmaceuticals Limited pay a dividend?
Yes. Jagsonpal Pharmaceuticals Limited pays 1.11% of its share price as dividends a year, higher than 82% of dividend-paying Healthcare companies in India.
Is Jagsonpal Pharmaceuticals Limited's revenue growing?
Revenue rose 7% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.